Deficiencies of Bruton's tyrosine kinase (Btk) have been implicated in the pathogenesis of human X-linked agammaglobulinemia (XLA). The distinctive phenotype observed in B-cell deficiency indicates the crucial role of Btk in B-cell development. This report describes a nationwide study of Btk deficiency in Japan, covering 51 XLA patients (35 independent families). Along with the identification of mutations, the resulting protein products were characterized by an in vitro kinase assay and a Western blot analysis. Thirtyone of the families were found to have mutations in the coding region of Btk. Although mutations were not found RUTON'S TYROSINE KINASE (Btk) is a cytoplasmic B tyrosine kinase recently identified as the defective gene in human X-linked agammaglobulinemia (XLA).13 XLA, which shows a typical B-cell deficiency characterized by a profound hypogammaglobulinemia and an absence of circulating mature B cells,3 is an autonomous B-lineage defect caused by a block in early B-cell de~elopment.~ Several studies have identified Btk mutations in XLA patient^.'.'^ Btk was also reported as the defective gene in murine Xlinked immunodeficiency (XID).zO,z' XID is characterized by unresponsiveness to thymus-independent type-I1 antigens and shows a moderate decrease in total B-cell numbers and a selective loss of some Ig subclasses such as IgM and IgG3." Although the expression of Btk mRNA and Btk kinase activity remained unaltered in the B cells of XID mice, the murine Btk gene was mapped exactly to the XID locus and a missense mutation (Arg28 to Cys, XID mutation) was found in the conserved domain of the Btk aminoterminal unique region of XID mice. The arrest of early B-lymphoid development in XLA, along with the B-cell deficiency in XID, indicates the crucial role of Btk in the B-cell-signaling pathway.
B tyrosine kinase recently identified as the defective gene in human X-linked agammaglobulinemia (XLA).13 XLA, which shows a typical B-cell deficiency characterized by a profound hypogammaglobulinemia and an absence of circulating mature B cells,3 is an autonomous B-lineage defect caused by a block in early B-cell de~elopment.~ Several studies have identified Btk mutations in XLA patient^.'.'^ Btk was also reported as the defective gene in murine Xlinked immunodeficiency (XID).zO,z' XID is characterized by unresponsiveness to thymus-independent type-I1 antigens and shows a moderate decrease in total B-cell numbers and a selective loss of some Ig subclasses such as IgM and IgG3." Although the expression of Btk mRNA and Btk kinase activity remained unaltered in the B cells of XID mice, the murine Btk gene was mapped exactly to the XID locus and a missense mutation (Arg28 to Cys, XID mutation) was found in the conserved domain of the Btk aminoterminal unique region of XID mice. The arrest of early B-lymphoid development in XLA, along with the B-cell deficiency in XID, indicates the crucial role of Btk in the B-cell-signaling pathway.
Similar to other cytoplasmic tyrosine kinases, Btk contains a catalytic domain (SHl domain) and two protein interaction domains called the SH2 and SH3 domains.' On the other hand, the presence of the PH (pleckstrin-homology) domain is a distinctive feature of Btk and its related kinasesz3 ( T~C ?~ Itk," B~nx,'~ T x~, '~ and Dsrc28C2'). The XID mutation was the first naturally occuring mutation identified within the PH domain. Identification of the Btk mutations in XLA has documented an extensive variability of these mutations, indicating that all domains of the Btk protein are necessary for human B-cell development. However, in most of these reports, the Btk proteins derived from mutated genes have not yet been characterized, and the consequences of these mutations at the protein level are not clear. A case report7 on an atypical XLA patient showed that a missence mutation in the SH2 domain resulted in instability of the Btk protein rather than in a functional defect of the domain. This observation stressed the importance of protein analysis in conjunc- tion with the identification of gene defects. Therefore, the precise characterization of the mutated Btk protein and its kinase activity is a prerequisite for understanding the molecular basis of Btk deficiency.
The present report describes a nationwide study of Btk deficiency in Japan, which covered 51 XLA patients in 35 independent families (representing more than half of the XLA population in Japan). The screening of Btk genes of these patients resulted in the identification of several new mutations, which helped to clarify the presence of missense mutation hot spots in the Btk gene. The consequences of these mutations were then evaluated at the protein level, which clarified the effect of mutations on kinase activity and protein stability. The primer pairs A to G (coresponding to the arrows in Fig 2) were used to amplify the coding region of the cDNA. The nucleotide sequence designation of the cDNA are from Vetrie et al.'
and their family members gave us their informed consent before their inclusion in this study. RNA was extracted from peripheral blood mononuclear cells (MNCs) and subjected to reverse transcription-PCR-single-strand conformational polymorphism (RT-PCR-SSCP) analysis. Briefly, MNCs were prepared from heparinized blood by means of Ficoll-Paque (Pharmacia, Uppsala, Sweden) separation and washed twice in Hanks' solution. As for the sequencing of the cDNA of the carrier's B cells. the peripheral B cells were prepared from MNCs by using twice E-rosette treatments (incubation of MNCs with sheep red blood cells on ice for 60 minutes, followed by Ficoll-Paque separation). RNA was extracted from 5 X 10" MNCs (or B cells) with the ISOGEN (Nippon Gene, Tokyo, Japan) method and resuspended in diethyl pyrocarbonate (DEPC) water (100 nglpL). The RT reaction was performed in a volume of 10 The incubation was performed at 37°C for 60 minutes and was followed by enzyme inactivation at 97°C for 5 minutes. The Btk gene was amplified from cDNA by using seven overlapping PCR primers. A to G. as shown in Table 2 (partially following the method described in Bradley et ais). The PCR reaction was performed in a volume of 50 Representative SSCP analysis of the PCR products from the X U patients. Fragments were amplified from the cDNA, digested with the restriction enzyme (see Table 2 ). and electrophoresed in a nondenaturing gel. Corresponding control subjects are shown in the left lanes.
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For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From total of 4 p L of the digested product and 36 pL of loading buffer (95% formamide, 10 mmol/L EDTA, 0.05% bromophenol blue, and 0.05% xylene cyanol) was denatured at 97°C for 5 minutes and rapidly cooled on ice. Two microliters of the samples was loaded onto a nondenaturing gel (5% polyacrylamide, 5% glycerol, 0 . 5~ TBE [SO mmol/L Tris, 49.5 mmol/L bolic acid, 1 mmol/L EDTA]) and electrophoresed in I X TBE buffer at 35 W at 20°C for 150 minutes. Gels were dried and exposed to autoradiograph films (Fuji Corp, Tokyo, Japan) at -80°C for I day.
The PCR products were purified through polyethylene glycol precipitation before sequencing. A mixture of 50 p L of PCR product, 30 pL of 20% PEG 6,000/2.5 mol/L NaCI, and 3 pL of 100 m m o l n EDTA (pH, 8.0) was placed on ice for 15 minutes. The precipitate was collected by centrifugation at 18,OOg at 4°C for 15 minutes, rinsed with 75% ethanol, dried, and dissolved to I x TE. The sequencing reaction was performed by using the dye deoxy terminator cycle sequencing kit (Applied Biosystems, Foster City, CA) with an automated ABI373A DNA sequencer. The same primers as shown in Table 2 were used. Detected mutations were confirmed by sequencing from the opposite direction.
Btk was immunoprecipitated from peripheral blood polymorphonuclear (PMN) cells with anti-Btk antiserum and was subjected to in vitro kinase assay.' The PMN cells were prepared by collecting the lower band of Polymorphprep (Nycomed. Oslo, Norway) separation from heparinized blood. A total of 1 X 10' PMN cells was lysed with 1 mL of the cell lysis buffer ( I % Triton X-100, 10 mmol/L phosphate buffer [pH, 7.01, 150 mmol/L NaCl, 5 mmol/L EDTA, I mmol/L phenylmethyl sulfonyl fluoride, 10 pg/mL leupeptin, and 10 pg/mL aprotinin) for 5 minutes on ice and was centrifuged at 18,OOOg for 10 minutes. The supernatant was incubated with 7 p L of anti-Btk antiserum (prepared by the same method as described by Tsukada et al') on ice for 60 minutes and was followed by conjugations with protein A sepharose beads at 4°C for 60 minutes. The beads were then washed 4 times (2X with I mL of the cell lysis buffer, I X with 1 mL of the kinase buffer [20 mmol/L PIPES: pH, 7.01, and 1 X with 1 mL of the reaction buffer [kinase buffer containing 20 mmol/L MnCI,]) and finally were suspended with 40 pL of the reaction buffer. The in vitro kinase y was performed by incubating the beads with 2 pL (I0 pCi) -32P-adenosine triphosphate (Amersham) at 30°C for 10 minutes. After the reaction, the beads were washed 3 times with 1 mL of the washing buffer (1% Triton X-100, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 0.1% NaCI, 10 mmol/L phosphate buffer [pH, 7.51, and 5 mmol/L EDTA), mixed with 40 pL of the loading buffer (2% SDS, 0.1 molL Tris [pH 6.81, 20% glycerol, 5% 2-mercaptoethanol, and 0. I % bromophenol blue), denatured at 97°C for 5 minutes, and placed on ice. The samples were loaded onto a 10% SDS-polyacrylamide gel and electrophoresed: samples were then dried and autoradiographed. At the same time, Hck, one of the Src family of tyrosine kinases expressed in PMN cells. was immunoprecipitated with anti-Hck antiserum (Santa Cruz Biotechnology, Inc, Santa Cruz, CA) from the same cell lysates and was followed by in vitro kinase assays performed in the reaction buffer (kinase buffer containing 10 mmol/L MnCl, and 10 mmol/L MgCI,) to show the availability of the PMN cells.
The amounts of the Btk transcripts in cells were estimated by coamplification of cellular cDNA with a competitive t e m~l a t e .~~. '~ The competitive template was made by deleting 64 bp (nucleotides no. 1229-1292*; 2 Pst I sites were used) of the Btk cDNA. The primers used for CRT-PCR were S'CACTGAAGCAGAAGACTCC3' (nucleotides no. 939-957) and SCTTCAAGAAGGTCAGGTCCT3' (nucleotides no. 1332-1 350), which yielded a 412-bp fragment for the cellular cDNA and a 348-bp fragment for the competitive DNA. PMN cells were prepared from P7, P29, P30 and a normal control by purification once with
Sequencing.
I n vitro kinase assay.
Competitive RT-PCR (CRT-PCR).
Polymorphprep separation and subsequently with Ficoll-Paque separation to avoid contamination with B cells. RNA extraction and RT reaction were performed as described above. For P33, cDNA derived from an Epstein-Barr virus (EBV)-induced B-cell line was used. The target cDNA (100 ng) was coamplified with a dilution series of the competitive DNA (8 X IO4 to 5 X Io' molecules). The PCR reaction was performed as described above (30 cycles at 95°C for 30 seconds, at 54°C for 30 seconds, and at 72°C for 30 seconds). A pilot study showed that the PCR reaction remained in the exponential phase under these conditions. After the reaction, the samples were electrophoresed in agarose gel and stained with ethidium bromide. The amounts of Btk cDNA were indicated by the amounts of the competitive DNA that most nearly equaled the amplification. To ensure that the amount of cDNA in the samples was the same, the amounts of the a-actin cDNA (accession no. M10277; GenBank. Cambridge, UK) were evaluated as an internal mRNA control. The PCR primers used for the amplification of the p-actin cDNA were 5'TGGACT-TCGAGCAAGAGATG3' (in exon 4) and S'GATCTTCATTGT-GCTGGGTG3' (in exon 5), which yielded a 320-bp fragment from the cellular cDNA. A PCR fragment amplified from the genomic DNA (415 bp, which contained the intron 4 (95-bp) sequence) was used as a competitive DNA. The PCR condition was 33 cycles at 95°C for 30 seconds, at 56°C for 30 seconds, and at 72°C for 30 seconds.
The monoclonal antiBtk antibody 48-2H was generated as follows: Mice were immunized with a fusion protein consisting of glutathione S-transferase (GST) and the SH3 domain (amino residue 2 12-275) of the Btk gene. After immunization. the spleen cells were fused with SP2/0 cells, and the hybridomas were selected by conventional hypoxanthineaminopterin-thymidine (HAT) selection. The supernatant of the hybridoma was then screened by enzyme-linked immunosorbent assay using GST-Btk (SH3) or GST alone. The antibodies from several clones bound to GST-Btk (SH3) but not to GST alone. One of these clones, 48-2H, was further characterized. Western blotting using 48-2H detected a 77-kD band in the lysate of PA317 cells that were transfected with Btk cDNA but did not detect this band in the lysate of nontransfected PA317 cells (data not shown). A further characterization of this monoclonal antibody will appear in another report.
For Western analysis, 2 X lo6 PMN cells were lysed with 20 pL of the lysis buffer ( I % NP40, 10 mmol/L Tris HCI [pH, 7.51, IS0 mmol/L NaCI, 5 mmoVL phenylmethyl sulfonyl fluoride, 10 pg/mL leupeptin, 10 pg/mL aprotinin, I pg/mL pepstatin A, IO pg/mL benzamidine, and 2 mmol/L iodoacetamide) for 10 minutes on ice and were centrifuged. The supernatant was mixed with an equal volume of SDS sample buffer and boiled for 5 minutes. The samples were then electrophoresed on 5% to 15% gradient SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride (PVDF) membranes (Immobilon P: Millipore Corp, Bedford, MA). The membranes were processed as follows: blocking with 5% The amplified cDNA fragments from some patients were different in molecular size from those of normal controls, indicating the existence of deletions or insertions. These fragments were directly sequenced. The SSCP analysis of other patients' Btk showed that only one PCR fragment of each patient (except P34, see below) had an altered singlestrand conformation that indicated a mutation (Fig l) , whereas a known silent polymorphism in the Btk gene (C1 T polymorphism at the 2031 nucleotide5) was frequently observed. (The frequency of C and T at this nucleotide in Japanese subjects was 47% [55 of 1161 and 53% [61 of 1161, respectively.) These mutations were confirmed by sequencing. Our SSCP assay of cDNAs derived from 1 1 patients (W, P19, P20, P22, P23, P24, P27, P29, P30, P32, and P33) did not show any conformational alterations. Subsequently t Nucleotide changes that caused aberrant splicings were identified on the genomic DNA (see Fig 3 and the text).
Monoclonal antibody and Western blot.
RESULTS
Identification
*The 3'-terminal half of the cDNA was not amplified, suggesting a large deletion. § The 5';terminal half of the cDNA was not amplified, suggesting a large deletion.
1) A stop codon appeared in the intron sequence.
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566 sequencing was performed for all of the coding regions of Btk cDNA from these patients. A direct sequencing method without any cloning procedures of PCR products was used to prevent a potential source of errors caused by possible misincorporation by Taq polymerase. This analysis allowed us to identify single base substitutions in 7 patients (P19, P20, P22, P23, P24, P27, and P32). No nucleotide change was found in the Btk coding region of the 4 other patients (P7, P29, P30, and P33). For the patients who showed aberrant splicing, the genomic DNA was further analyzed, and the responsible mutations were identified. The Btk mutations identified in these patients are summarized in Table 3 and Fig 2 (These mutations were submitted to "Btk base", the database of known Btk mutations'' used for international studies.) Single base substitutions were identified in the Btk coding regions of 16 independent XLA families; mutations in 8 of these families resulted in single amino acid substitutions in the SHl (5 families), SH2 (1 family), and PH (2 families) domains. These mutations are further characterized in the next section. Single base substitutions causing premature stop codons were found in 8 families. Deletions or an insertion in the coding region were detected in 15 independent families; the Btk of 10 of these patients showed aberrant splicings (summarized in Fig 3) . The Btk of 3 patients (P12, P13, and P26) showed similar types of deletions that were located in the 5' terminal of the exonslO.l 1.32 and had five bases with the AGAAG sequence. In these Btk genes, the splicing acceptor signals had been altered (A -+ G at position -2 [intron 21 in P12, A -+ G at position -2 [intron 31 in P13, A + G at position -2 [intron 31 in P26) and replaced by the 4-base downstream AG sequences. In P25, whose Btk missed one base at the boundary of exons 11 and 12, the sequencing of the genomic DNA showed a G + A change at position -1 of intron 11, which resulted in a new acceptor site with A at position -1 of intron 11 and G at position +1 of exon 12. In P15, 136 bases in the 3'-terminal of exon 8 were deleted. Sequencing of the genomic DNA showed that a G -+ A change at position +1 of intron 8 resulted in an activation of a cryptic splice donor site in exon 8 (G773TGAG...). Similarly, P21 showed 23-base deletion in the 3'-terminal of exon 2. In this patient's genomic DNA, AZ5, in exon 2 was found to have changed to G, resulting in a cryptic splicing donor site (G251TGAG...). In P31, a 60-base insertion was found at the boundary of exons 16 and 17. Sequencing of the genomic DNA showed a G -+ C change at position +1 of intron 16 donor site of P31, resulting in an activation of a cryptic donor site in intron16 (G,,,TAGG ...) and an addition of 60 bases to the cDNA sequence. (The same alteration was reported in Jin et all6). In P28, who showed exon-16 skipping, an A --t G substitution was found at position -23 of the intron 15 (23 bp upstream from the boundary of intron 15 and exon 16). Because no other substitutions were detected in any of the exons or in introns 15 and 16, it is likely that the observed A-z3 -+ G mutation was responsible for the exon-16 skipping. Presumably, this adenine is located at the branch point of the splicing intermediate, because it is known that the branch points are located at a distance of I8 to 37 nucleotides before the splicing acceptor sites.25 The sequence around this adenine (GTCTCA-,,C) is consistent with the branch-point consensus sequence with a 5n fit"' or 415 fit, and the same CTCAC sequence has been reported at the branch point in the a-globin gene." In P28, this point mutation at the potential branch point may have altered the affinity of the acceptor site of intron 15, thus resulting in the exon-l6 skipping. A similar type of defect was reported in a patient with erythropoietic protoporphyria.." It is worth noting here that the moderate phenotype of P28 (Table 1) may be related to the mutation in the less conserved region of the intron (a trace amount of normal-sized cDNA was detected in the PCR product of this patient). For the case of p9 who showed exon-15, -16, and -17 skipping, sequencing of the genomic DNA showed no alteration in any of the exons or of the introns 15, 16, 17, and 18, suggesting that some mutation located apart from the skipping site is responsible. The other patients were found to have deletions of various lengths in their Btk coding regions, resulting in premature terminations (P3, P8, PI I , and P35) or a truncated form (P4). The gross rearrangements in the Btk genes of P4, PI l , and P35 were confirmed by Southern blot analysis (data not shown). The PCR-SSCP analysis of P34 manifested an exceptional result (Fig 4) . Three alterations, a nonsense mutation (Tyr142 -+ stop) and two discontinuous exon skippings (one for exon I 1 and the other for exons 15 and 16), were found in the Btk cDNA of this patient. Further PCR-sequencing analysis showed that these three alterations were located on the same cDNA (Fig 4) and did not reflect a mosaicism. On the contrary, the sequencing of the genomic DNA showed only a T558 + G transition that caused the stop codon but no abnormalities in the skipped exons or the neighboring introns. A possible mechanism for this unusual alteration is described in the Discussion.
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Characterization of Rtk mutations. To characterize the altered Btk proteins, the Btk kinase activities in XLA patients were evaluated by using an in vitro kinase assay. Because of the very small number of peripheral B cells in typical XLA patients, we used their PMN cells for the in vitro kinase assay. Although the Btk kinase activity detected in PMN cells is less than 10% of that in MNCs (Fig S) , the activity can be reproducibly detected in PMN cells of healthy controls even from l-day-old blood samples. Cell lysates from PMN cells were immunoprecipitated with anti-Btk antiserum and assayed for autokinase activity. In PMN cells from healthy contols or obligate carriers of XLA, a 77-kD band of autophosphorylation was clearly detected (Fig 5) . As expected from the result for molecular alterations, no kinase activity was detected in the mutated Btk with nonsense mutations or deletions in the Btk coding region (Table 3) . Although the nucleotide sequence of the Btk gene of P4 might lead one to predict a truncated protein with an intact SHI domain, Btk kinase activity was not detected, suggesting instability of the mRNA or of the truncated protein. To exclude the possibility of a nonspecific protein' degradation, the autokinase activity of an unrelated kinase, Hck, was examined by using the same cell lysate. The result showed equivalent levels of Hck activity in all of the PMN cell lysates (data not shown).
Also, no Btk kinase activity was detected in 4 other patients (P7, P29, P30, and P33) for whom our assay did not find any mutations in the coding region, suggesting a reduced amount of the normal Btk transcript. To confirm this observation, semiquantifications of the Btk mRNA were performed by using a CRT-PCR assay (Fig 6) . The amounts of the Btk transcripts were found to be less than 10% of those of normal controls in either the PMN cells (W, P29 and P30) or an EBV-induced B-cell line (P33). cells of these patients (Fig 7) showed the presence of Btk proteins in P5 and PI7 but not in PI4 and P16. These data indicate that the mutations in the SHl domain resulted in a functional defect of the domain in P5 and PI7 but in an instability of the protein in P14 and P16.
Strikingly, normal levels of Btk kinase activity were detected in PMN cells from the 2 patients with single amino acid substitutions in the PH domain (Lysl2 to Arg [PI81
In vitro kinase assay of Btk. Each assay was performed by using the lysate of 1 x lo7 PMN cells, and Btk kinase activity was detected as a 77-kD band of autophosphorylation. In healthy control, the Btk kinase activity in PMN cells is less than 10% of that in the same number of MNCs (shown in the left lanes). Of 35 XLA families, only 3 cases (P18, P23, and P32) showed a normal level of Btk kinase activity. These patients had missense mutations in either the PH or the SH2 domain ("*" indicates the location of the mutations). Btk kinase activity was not detected in other XLA families, including those having missense mutations in the SH1 domain and those having no mutations in the coding region of Btk.
For and Arg28 to Pro [P23]), implying that these substitutions in the PH domain did not affect the kinase activity or the stability of altered proteins. In addition, the Btk containing an SH2 domain mutation (Gly302 to Glu [P32]) also showed a normal level of kinase activity, which was a different result from that for a previously reported SH2 mutation (Tyr361 to Cys) that showed a decreased stability of the protein. ' Because the kinase assay did not show any alterations at the protein level, the usage of the two (normal and mutated) Btk genes was examined in the peripheral B cells of the obligate carriers to determine the X-linked inheritance and the preferential use of the X chromosome containing the normal Btk gene. It has been reported that the peripheral B cells in obligate carriers of XLA showed a skewing of X chromosome inactivation, which is assumed to arise from a growth disadvantage of cells in which a defective X-linked gene is active.'R Although several of the Btk mutations are known to reduce the amount of mRNA,'.'' the normal kinase activities in P18, P23, and P32 indicated that the mutations in these patients did not alter the stability of the mRNA. Therefore, the proportion of mRNA from the normal and mutated genes in a B-cell population reflects the number of B cells expressing either of these genes. The B cells were purified from the peripheral blood of the obligate carriers of these patients as described in Materials and Methods. The cDNA was PCR-amplified and directly sequenced. As shown in Fig  8 (middle lanes) , the major part of the cDNA showed the wild-type Btk sequence, indicating that the majority of the Btk P-Actin carrier's B cells expressed the normal Btk. To confirm the inheritance of these mutations, the genomic DNA of the obligate carriers was directly sequenced. The result showed the presence of both the normal and mutated genes on the genome (Fig 8, lower lanes) . These observations indicate that the activation of the X chromosome bearing the altered Btk gene inhibited the B-cell development, thus suggesting the relevance of Btk alteration for the phenotypes of these patients.
DISCUSSION
The Btk genes and derived protein products of 35 independent families (5 1 patients) in Japan have been characterized in this study. In Japan, 70 to 80 patients are currently recognized as XLA"9; therefore, this study covers more than half of the XLA population. A complementary report on 12 XLA families in Japan was recently published.'* Only 1 XLA family was studied in both reports (P1 in this report belonged to the same family as P14 in Kobayashi et allR). In 31 of 35 families, mutations were identified in the coding region of Btk; these mutations included seven novel missense mutations. The SSCP and direct sequencing of the total coding region failed to find any mutations in the cDNA of 4 patients (P7, P29, P30 and P33). However, the in vitro kinase assay indicated the absence of Btk kinase activity in the PMN cells of these patients, and the semiquantification by a CRT-PCR showed a reduction in the amount of the mRNA. These observations suggest that some genetic alterations that could not be identified by our assay may have caused a reduced transcription, an instability of the Btk mRNA, or a splicing defect. In addition to the coding region, the putative promoter region"' in the genomic DNA of these patients was sequenced, but no mutation was detected. The precise characterization of the genetic defect of these patients is now in progress.
The abnormality manifested in the cDNA of P34 was unusual. Three alterations were found in the same cDNA, although the sequencing of the genomic DNA only showed a single nucleotide substitution causing the nonsense codon and did not detect any other mutations in the exons or the exon-intron boundaries. Therefore, it is likely that the single nucleotide substitution that caused the nonsense codon is responsible for the aberrant splicing in P34. It has been reported that single nucleotide substitutions in exons resulted in aberrant splicings in cases of the phosphofructokinase muscle subunit gene,40 the dihydrolipoyltransacylase gene:' the thyroglobulin gene:* and the hypoxanthine-guanine phosphoribosyltransferase gene.43 It was also reported that, in a patient of the inherited medium-chain acyl-CoA dehydrogenase deficiency,u a single nucleotide substitution in an exon was associated with a high rate of missplicing and resulted in multiple, discontinuous exon skippings. In addition, an in vitro experiment4' has shown that some mutation within an exon could dramatically alter the downstream processing of the mRNA. Presumably, some single nucleotide substitution may have had a disruptive effect on the entire secondary structure of the mRNA and may have resulted in the failure of the splicing complex to recognize the correct splicing sites.
For the analysis of altered Btk proteins in XLA patients, EBV-induced B-cell lines have been successfully used.'.'.' However, it is often difficult to establish cell lines from the very small number of peripheral B cells observed in XLA patients. Therefore, in this study, PMN cell fractions were used to characterize the Btk protein. Despite the low expression level of the Btk protein and the instability of neutrophiles, the Btk kinase activity was reproducibly detected in healthy controls and obligate carriers because of the high sensitivity of the in vitro kinase assay. Btk kinase activity was not detected in 32 of 35 XLA families (91%). which indicated that most of the Btk mutations in XLA resulted in the loss of kinase activity. This also suggests that the Btk kinase activity assay can be valuable as an initial screening for XLA.
A combination of in vitro kinase assay and Western blot showed different consequences of the four SHI domain mutations. Two of the mutations (Cys502 + Trp and Asp521 + His) resulted in a functional defect of the SHI domain, but the other two (Cys633 + Tyr and Phe644 + Ser) resulted in a protein instability. This observation made it clear that the effect on protein stability needs to be considered in the interpretation of missense mutations in the SHI domain. Among the four novel missense mutations in the SHI domain identified in this study, Asp521 is one of the invariant residues throughout the protein kinase^.^' Cys633 and Phe644 are also well conserved among tyrosine kinases but not among serine-threonine kinases, whereas Cys502 occurs as a conserved residue only in the Btk subfamily (Btk, T~c ,~~ Itk," Bmx," Txk," Dsrc28C,ZX and Rlk4'). Most of the missense mutations in the SHI domain reported so far, including the four mutations identified in this study, are located in the C-terminal half of the domain (the larger lower lobe4'). In particular, a small array of seven amino acid residues (from Arg520 to Asn526 in subdomain VIB) is highly mutated. More than six missense mutations including the Asp521 to His mutation in this study have been spotted in this regi~n.~.~.l"~'*.l~ This RDLAARN motif (catalytic loop) has been implicated as an indicator of tyrosine specificity of protein kinases:' A recent report on the crystal structure of insulin receptor tyrosine kinase49 showed that two residues (corresponding to Asp521 [mutated in PI71 and Arg525 of Btk) in this catalytic loop are hydrogen-bonded to a Tyr residue (corresponding to Tyr55 I of Btk, autophosphorylation site) in subdomain VI1 and underscored the role of the amino acid residues in the catalytic loop in phosphotransfer reaction. Mutations of Asp521 (reported in this study) and Arg525" in this loop were shown not to change the protein stability but to abrogate the kinase activity. On the other hand, the two mutations (Cys633 + Tyr and Phe644 + Ser) that resulted in protein instability were located in the bottom of the larger lower lobe, called subdomain XI.4R Although the functional significance of this subdomain is not clear, these residues may be critical for determining the tertiary conformation of the SHI domain and for stabilizing the pro- tein. No difference in phenotype was recognized between these two types of mutations that showed different effects on the molecule (Table 1) . Several missense mutations in the Btk PH domain of XLA patients have been reported, including Phe25 + Ser,14 Arg28 + Hi~,6.''.'~ Thr33 --f Pro,I3 Val64 + Phe," Val1 13 + Asp," and Ser 14 --f Thr.Ig However, the protein products of these altered Btk genes have not been characterized, and it is not clear whether these mutations actually change the function of the PH domain, decrease protein stability, or are just simple polymorphisms. In this report, we described two novel mutations in the Btk PH domain. These two mutations (Arg28 + Pro [P23] and Lysl2 + Arg [P18]) were found not to change the kinase activity of the mutated Btk, which also suggested that these mutations did not affect protein stability. The preferential use of the X chromosome bearing the nonaltered Btk in the B cells of the obligate carriers suggests the relevance of Btk alterations for the phenotypes of the patients, although we cannot exclude the possibility that some alteration in another gene on the same chromosome may inhibit B-cell development. Among eight PH domain mutations identified so far, six were located in a short stretch (amino acids no. 12 to 33) near the N-terminus of the Btk PH domain. As suggested also by others:' this Nterminal region of the Btk PH domain may form a binding site with unidentified molecules. The Arg28 + Pro and Lysl2 + Arg mutations, along with other mutations in this region, may inhibit this interaction that is crucial for Bcell development. In addition, the identification of the novel Arg28 mutation reported here further underscored the importance of this amino acid residue. Notably, the identification of Arg 28 + Pro mutation in a typical XLA patient seem to lend further support to the hypothesis that the different phenotypes of Arg28 mutations in human (Arg28 + Pro or His, severe phenotype) and mouse (Arg28 + Cys, mild phenotype) reflect a species-related difference in B-cell de~elopment~,'~ rather than a difference in mutated amino acids at Arg28. The phenotypes of Btk-deficient m i~e "~~~ also appear to support this hypothesis.
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